Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 56 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 OncoNPC Classifier Identifies CUP Subgroups Sharing Characteristics with Predicted Primaries and... September 6, 2023 Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 Anal Cancer Advances Open Door to Screening and Prevention June 7, 2024 Load more HOT NEWS Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment... Navigating Life During and After Cancer As a Young Adult: A... New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... The link between Down syndrome and childhood leukaemia
